

NGS PANEL REQUISITION

PATIENT INFORMATION (COMPLETE ONE FORM FOR EACH PERSON TESTED)

Patient Last Name	Patient First Name	MI	/	/	Date of Birth (MM / DD / YYYY)
Address	City	State	Zip	Phone	
Accession #	Hospital / Medical Record #	Genetic Sex: <input type="radio"/> Female <input type="radio"/> Male <input type="radio"/> Unknown		Gender identity (if different from above): _____	

ORDERING PHYSICIAN

ADDITIONAL REPORTS

Ordering Physician	Institution Code	Name	Name
Institution Name	Email (Required for International Clients)	Email	Email
Phone	Fax	Phone	Phone
		Fax	Fax

Note: Reports will be sent by FAX except for international recipients

PAYMENT (FILL OUT ONE OF THE OPTIONS BELOW)

SELF PAYMENT

Pay With Sample Bill To Patient

INSTITUTIONAL BILLING

Institution Name	Institution Code	Institution Contact Name	Institution Phone	Institution Contact Email
------------------	------------------	--------------------------	-------------------	---------------------------

INSURANCE

Do Not Perform Test Until Patient is Aware of Out-Of-Pocket Costs (excludes prenatal testing)

- REQUIRED ITEMS**
- | | |
|--|---------------------------------------|
| 1. Copy of the Front/Back of Insurance Card(s) | 2. ICD10 Diagnosis Code(s) |
| 3. Name of Ordering Physician | 4. Insured Signature of Authorization |

Primary Insurance Co. Name	Primary Insurance Co. Phone	Secondary Insurance Co. Name	Secondary Insurance Co. Phone
Primary Member Policy #	Primary Member Group #	Secondary Member Policy #	Secondary Member Group #
Name of Insured	Insured Date of Birth (MM / DD / YYYY)	Name of Insured	Insured Date of Birth (MM / DD / YYYY)
Patient's Relationship to Insured	Phone of Insured	Patient's Relationship to Insured	Phone of Insured
Address of Insured		Address of Insured	
City	State	Zip	
		City	State
			Zip

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates. If self-pay is selected, I agree to pay for the cost of testing ordered and billed by Baylor Genetics as outlined in the Good Faith Estimate I received. I understand that I am responsible for sending Baylor Genetics any and all payments that I receive directly from my insurance company in payment for this test. Please note, Medicare may not cover certain screening tests.

Patient's Printed Name	Patient's Signature	/	/	Date (MM / DD / YYYY)
------------------------	---------------------	---	---	-----------------------

STATEMENT OF MEDICAL NECESSITY (REQUIRED)

This requisition hereby incorporates the Terms and Conditions of the Laboratory Services found at <https://www.baylorgenetics.com/lab-terms-conditions/> or, in the case of international entities, <https://www.baylorgenetics.com/terms-conditions-of-the-laboratory-services-international/>. This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient, and they have consented to genetic testing.

Physician's Printed Name	Physician's Signature	/	/	Date (MM / DD / YYYY)
--------------------------	-----------------------	---	---	-----------------------

NGS PANEL REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

INSTRUCTIONS FOR ORDERING

Listed below are testing options that allow for comprehensive assessment to increase the diagnostic yield for patients with a focused disease phenotype. Any combination of panel testing or Chromosomal Microarray Analysis (CMA) can be ordered. Please note that the turnaround time may differ for each test.

DISEASE-SPECIFIC PANELS | 1300

NEUROMUSCULAR PANELS

BG-1300-P142-1 Neuromuscular Disorders Panel

IMMUNOLOGY PANELS

BG-1300-P463-1 Primary Immunodeficiency Panel

If panel result is negative, reflex to test code 1520, Whole Exome Sequencing Reflex.

NEUROLOGY PANELS

BG-1300-P397-1 Epilepsy Panel

BG-1300-P76-1 STAT Epilepsy Panel

BG-1300-P236-1 Neurodevelopmental Disorders Panel

BG-1300-P419-1 Cerebral Palsy Spectrum Disorders Panel

SKELETAL PANELS

BG-1300-P354-1 Skeletal Disorders Panel

CONNECTIVE TISSUE PANELS

BG-1300-P92-1 Connective Tissue Disorders Panel

ADDITIONAL TESTING OPTIONS

- 8665 Chromosomal Microarray Analysis (CMA)-HR+SNP Screen (Comprehensive)
- 2055 Comprehensive mtDNA analysis by NGS
- 6573 FMR1 CCG Repeat Expansion Analysis
- 6350 DMD Deletion/Duplication Analysis
- 6006 Angelman Syndrome Methylation Analysis

SAMPLE TYPES

Please refer to www.baylorgenetics.com for full sample requirements.

- | | | |
|--|--|--|
| <input type="radio"/> Blood in EDTA | <input type="radio"/> Cultured Skin Fibroblast | _____ / _____ / _____
Date of Collection (MM / DD / YYYY) |
| <input type="radio"/> Buccal Swab | <input type="radio"/> Saliva | |
| <input type="radio"/> Extracted DNA from _____ | <input type="radio"/> Skin Biopsy* | |

NOTE: Extracted DNA/RNA will only be accepted if the isolation of nucleic acids for clinical testing occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.

ITEM CHECKLIST FOR TESTING

- | | | |
|--|--|---|
| <input type="checkbox"/> Proband Sample (Required) | <input type="checkbox"/> Clinical Note/Summary | <input type="checkbox"/> Indication for Study |
| <input type="checkbox"/> Signed Consent Form | <input type="checkbox"/> Requisition | <input type="checkbox"/> Pedigree |

* This sample type incurs an additional fee and typically adds 14 days to the turnaround time, depending on sample quality.
† Baylor Genetics will store this sample for up to 14 days after the report is issued, allowing for follow-up testing if needed.

NGS PANEL REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

INDICATION FOR TESTING (REQUIRED)

Please provide the following clinical information regarding the patient to be tested. Please also submit a clinic note and pedigree, if available. Phenotypes listed are in HPO terms with the corresponding HPO number (<http://human-phenotype-ontology.github.io/>). This information is needed to facilitate interpretation of results. If the laboratory requires additional information, please indicate the health care provider to be contacted:

Physician Name _____ Physician Phone _____ ICD-10 Diagnosis Code(s) _____

PRE/PERINATAL HISTORY

- 0001622 Prematurity - GA at birth _____
- 0001511 Intrauterine Growth Restrictions
- 0001562 Oligohydramnios
- 0001561 Polyhydramnios
- 0000476 Cystic Hygroma
- 0000776 Congenital Diaphragmatic Hernia
- 0001508 Failure to Thrive
- 0001539 Omphalocele
- 0002084 Encephalocele
- 0010880 Increased Nuchal Translucency
- _____

EYE DEFECTS & VISION

- 0000505 Visual Impairment
- 0000618 Blindness
- 0000589 Coloboma
- 0000526 Aniridia
- 0000528 Anophthalmia
- 0000568 Microphthalmia
- 0000508 Ptosis
- 0000486 Strabismus
- 0000519 Cataract Congenital Bilateral
- _____
- _____

MOTOR/COGNITIVE DEVELOPMENT

- 0000750 Delayed Speech & Language Development
- 0001270 Delayed Motor Milestones
- 0002376 Developmental Regression
- Intellectual Disability
 - 0001256 Mild
 - 0002342 Moderate
 - 0010864 Severe
- 0000729 Autistic Spectrum Disorder
- _____
- _____

STRUCTURAL BRAIN ABNORMALITIES

- 0001360 Holoprosencephaly
- 0001339 Lissencephaly
- 0002084 Encephalocele
- 0000238 Hydrocephalus
- 0002119 Ventriculomegaly
- 0001273 Abnormality of Corpus Callosum
- 0002539 Cortical Dysplasia
- 0012444 Brain Atrophy
- 0002352 Leukoencephalopathy
- 0002269 Abnormality of Neuronal Migration
- 0002126 Polymicrogyria
- 0001302 Pachgyria
- 0002500 Abnormality of Cerebral White Matter
- 0007266 Cerebral Dysmyelination
- 0006808 Cerebral Hypomyelination
- 0002134 Abnormality of the Basal Ganglia
- 0002363 Abnormality of the Brainstem
- 0007360 Aplasia/Hypoplasia of the Cerebellum
- 0006817 Aplasia/Hypoplasia of the Cerebellar Vermis
- _____

NEUROLOGICAL

- 0001284 Areflexia
- 0200134 Epileptic Encephalopathy
- 0001250 Seizures
 - 0002373 Febrile Seizures
 - 0012469 Infantile Spasms
 - 0002123 Generalized Myoclonic Seizures
 - 0002069 Generalized Tonic-clonic Seizures
 - 0010818 Generalized Tonic Seizures
 - 0010819 Atonic Seizures
 - 0002121 Absence Seizures
 - 0011169 Generalized Clonic Seizures
 - 0001251 Ataxia
 - 0001332 Dystonia
 - 0002072 Chorea
 - 0001257 Spasticity
 - 0009830 Neuropathy
- _____
- _____

CRANIOFACIAL

- 0000256 Macrocephaly
- 0000252 Microcephaly
- 0001363 Craniosynostosis
- 0000204 Cleft Upper Lip
- 0000175 Cleft Palate
- 0000316 Hypertelorism
- 0000601 Hypotelorism
- 0008050 Abnormality of the Palpebral Fissures
- 0000286 Epicanthal Folds
- 0000288 Abnormality of the Philtrum
- 0010938 Abnormality of the External Nose
- _____
- _____

Indications continued on next page

NGS PANEL REQUISITION

Patient Last Name Patient First Name MI Date of Birth (MM / DD / YYYY) Genetic Sex

INDICATION FOR TESTING (REQUIRED) - CONTINUED

HAIR & SKIN

- 0000957 Cafe-Au-Lait Spots
- 0001034 Hypermelanotic Macule
- 0001010 Hypopigmentation of the Skin
- 0008066 Abnormal Blistering of the Skin
- 0008064 Ichthyosis
- 0000988 Skin Rash
- 0001581 Recurrent Skin Infections
- 0005306 Capillary Hemangiomas
- 0001597 Abnormality of the Nail
- 0004554 Generalized Hypertrichosis
- 0001596 Alopecia
- 0002208 Coarse Hair
- 0002299 Brittle Hair
- _____
- _____

CARDIAC

- 0001631 Atria Septal Defect
- 0001629 Ventricular Septal Defect
- 0001655 Patent Foramen Ovale
- 0001713 Abnormality of Cardiac Ventricle
- 0001636 Tetralogy of Fallot
- 0001680 Coarctation of Aorta
- 0001647 Bicuspid Aortic Valve
- 0002616 Aortic Root Dilatation
- 0001638 Cardiomyopathy
- 0011675 Arrhythmia
- _____
- _____

GENITOURINARY

- 0000113 Polycystic Kidney Dysplasia
- 0000107 Renal Cyst
- 0008738 Partially Duplicated Kidney
- 0000104 Renal Agenesis
- 0000085 Horseshoe Kidney
- 0000069 Abnormality of the Ureter
- 0000795 Abnormality of the Urethra
- 0000047 Hypospadias
- 0000028 Cryptorchidism
- 0000035 Abnormality of the Testis
- 0000062 Ambiguous Genitalia
- _____
- _____

RESPIRATORY

- 0002093 Respiratory Insufficiency
- 0002878 Respiratory Failure
- 0002104 Apnea
- 0002791 Hypoventilation
- 0002883 Hyperventilation
- 0002788 Recurrent Upper Respiratory Tract Infections
- _____
- _____

METABOLIC

- 0001946 Ketosis
- 0003074 Hyperglycemia
- 0001943 Hypoglycemia
- 0001941 Acidosis
- 0003128 Lactic Acidosis
- 0003215 Dicarboxylic Aciduria
- 0002490 Increased CSF lactate
- 0001992 Organic Aciduria
- 0030085 Abnormal CSF Lactate Level
- 00003542 Increased Serum Pyruvate
- 0003535 3-Methylglutaconic aciduria
- 0001942 Metabolic acidosis
- 0100493 Hypoammonemia
- 0001987 Hyperammonemia
- 0004923 Hyperphenylalaninemia
- 0003234 Decreased Plasma Carnitine
- 0003236 Elevated Serum Creatine Phosphokinase
- Abnormal Newborn Screen
- Unusual Color/Odor
- _____
- _____

MUSCULOSKELETAL

- 0011398 Hypotonia
- 0001276 Hypertonia
- 0000098 Tall Stature
- 0004322 Short Stature
- 0001382 Joint Hypermobility
- 0001371 Flexion Contracture
- 0002804 Arthrogryposis Multiplex Congenita
- 0001161 Hand Polydactyly
- 0001829 Foot Polydactyly
- 0006101 Finger Syndactyly
- 0001770 Toe Syndactyly
- 0100490 Camptodactyly of Finger
- 0012165 Oligodactyly
- 0001762 Talipes Equinovarus
- 0002757 Recurrent Fractures
- 0002650 Scoliosis
- 0002808 Kyphosis
- 0003307 Hyperlordosis
- 0001528 Hemihypertrophy
- 0001513 Obesity
- 0001548 Overgrowth
- 0002652 Skeletal Dysplasia
- _____
- _____

GASTROINTESTINAL

- 0002021 Pyloric Stenosis
- 0002575 Tracheoesophageal Fistula
- 0002032 Esophageal Atresia
- 0002020 Gastroesophageal Reflux
- 0001733 Pancreatitis
- 0002014 Diarrhea
- 0002019 Constipation
- 0002037 Inflammatory Bowel Disease
- 0004389 Intestinal Pseudo-Obstruction
- 0001399 Hepatic Failure
- 0002572 Episodic Vomiting
- 0001744 Splenomegaly
- 0002240 Hepatomegaly
- 0001508 Postnatal Failure to Thrive
- 0002578 Gastroparesis
- _____
- _____

Indications continued on next page

NGS PANEL REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

INDICATION FOR TESTING (REQUIRED) - CONTINUED

ENDOCRINE **HEMATOLOGY** **OTHER**

- 0000819 Diabetes Mellitus
- 0000873 Diabetes Insipidus
- 0000821 Hypothyroidism
- 0000829 Hypoparathyroidism
- 0000834 Abnormality of the Adrenal Glands
- 0001738 Exocrine Pancreatic Insufficiency
- 0002721 Immunodeficiency
- _____
- _____

- 0001875 Neutropenia
 - 0005549 Congenital
 - Chronic
 - Cyclic
- 0001873 Thrombocytopenia
- 0040185 Macrothrombocytopenia
- 0005537 Decreased Mean Platelet Volume
- 0005518 Erythrocyte Macrocytosis
- 0004444 Spherocytosis
- 0012410 Pure Red Cell Aplasia
 - Aplastic
 - Hypoplastic
- 0001903 Anemia
- 0005528 Bone Marrow Hypocellularity
- _____
- _____

- Organomegaly
- Chronic Infections
- 0004311 Abnormality of Macrophages
- 0001954 Episodic Fever
- 0004313 Hypogammaglobulinemia
- 0010701 Abnormal Immunoglobulins
- 0002721 Immunodeficiency
- 0012088 Abnormal urinary odor
- 0012537 Food intolerance
- 0008067 Abnormally lax or hyperextensible skin
- Abnormal Movements
- Family History of Similar Disorder
- 0001254 Lethargy
- 0002415 Leukodystrophy
- _____
- _____

EAR DEFECTS & HEARING

- 0000407 Sensorineural Hearing Impairment
 - 0008619 Bilateral
- 0000405 Conductive Hearing Impairment
- 0000410 Mixed Hearing Impairment
- 0004467 Preauricular Pit
- 0000384 Preauricular Skin Tag
- 0000369 Low-set Ears
- 000037 Abnormality of the Pinna
- _____
- _____

CANCER

- Type of Cancer _____
- Age of Diagnosis _____
- Family History of Cancer and Affected Relatives _____
- _____
- _____

GENES OF INTEREST

ADDITIONAL CLINICAL INFORMATION

DIFFERENTIAL DIAGNOSIS

Consent on next page

NGS PANEL REQUISITION

Patient Last Name Patient First Name MI / / _____
Date of Birth (MM / DD / YYYY) Genetic Sex

INFORMED CONSENT FOR GENETIC TESTING ON THE NGS PANEL REQUISITION

TEST INFORMATION

This consent form will provide you with information regarding genetic testing, which you should discuss with your healthcare provider or a genetic counselor. To assist you in understanding the reason for this testing, we have provided information about the testing process and potential results below.

The purpose of genetic testing is to determine if a genetic disease may be present or if there is an increased risk for a genetic disease to occur in a patient or their family. DNA is the genetic material that we receive from our parents. Genes are made of DNA and are the instructions for maintaining the health of our body. Each person has a unique set of DNA and most of the differences in our DNA do not impact our health. Genetic testing analyzes DNA to find any abnormal changes (mutations also called variants) that might cause disease, make it more likely to develop disease, and/or increase the chance of having a child affected by disease.

Most of the tests on this requisition, if ordered by your healthcare provider, will start being performed once your sample arrives at the laboratory. If your healthcare provider orders the whole exome sequencing (WES) test, this will only be performed if the results of other testing ordered do not explain the symptoms being experienced (WES will be run as a "reflex"). This testing provides a comprehensive analysis of the exome, which is the part of the human genome that helps the body make important proteins. The WES test will analyze the important regions of thousands of genes at the same time. Based on the symptoms that are known, genes with changes associated with these symptoms will be reported. It is possible that even if WES identifies the underlying genetic cause for a disease in a family this information may not help in predicting medical outcomes or changing medical management or treatment of disease. WES testing may also identify information about genes and diseases that have clear and immediate medical significance to your health or the health of your family members, even if that information is not related to currently known symptoms. You may consider discussing the significance of your results with your healthcare provider or genetic counselor.

The testing ordered by your healthcare provider can determine if you or your child have a variant associated with a genetic disease.

Depending on why genetic testing is needed, you might be tested for:

- A known variant that has already been found in your family
- A single gene or variant that causes a specific, suspected disease.
- Multiple genes at the same time. These genes might cause similar diseases or might cause diseases that are unrelated to each other.
- Multiple types of testing that each test for different variants.

RESULTS

There are several types of test results that may be reported including:

- **Positive:** Positive or "abnormal" results mean there is a change in the DNA found that is related to your/your child's medical issues or that you/your child are at an increased risk of developing a disease in the future. It is possible to test positive for more than one variant. Positive results might include pathogenic variants (variants known to be associated with disease) and likely pathogenic variants (variants that are likely to be associated with disease).
- **Negative:** Negative or "normal" results mean no relevant variants related to your/your child's medical issues were detected or that you/your child are not expected to be at an increased risk for developing a disease in the future. This might indicate that there are no variants associated with disease in the gene(s) tested. Genetic testing, while highly accurate, might not detect a variant present in the gene(s) tested. This can be due to limitations of the information available about the gene(s) being tested, or limitations of the testing technology.
- **Variant of Uncertain Significance:** Testing can detect variant(s) in DNA which we do not yet fully understand. These are also referred to as variants of uncertain significance (VUS). Additional testing may be recommended for you or your family if a VUS is identified in a gene that may be associated with your/your child's medical condition.
- **Secondary / Incidental Findings:** Testing can sometimes detect a variant in a person's DNA unrelated to the reason for testing. If this variant is expected to have medical or reproductive significance, it is called a secondary or incidental finding.

CONSIDERATIONS AND LIMITATIONS

- This consent form should only be used with the NGS Panel requisition. Consent forms for other requisitions are located at <https://www.baylorgenetics.com/consent/>.
- Results may indicate you have a genetic disease, are at increased risk to develop a genetic disease, and/or be at an increased risk to have a child with a genetic disease. It is important to understand that genetic tests, even if negative, cannot rule out every variant. It is not possible to exclude risks for all genetic diseases for you and your family members.
- Depending on the type of genetic testing performed and the results, additional genetic testing or other testing may be needed to fully understand the likelihood of your developing the disease or the severity of the disease. This additional testing might be needed for you/your child or other members of your family.
- It is recommended that you discuss genetic testing with your healthcare provider or genetic counselor before signing this consent and again after results are made available.
- It may not always be possible to complete testing, as sometimes the sample does not have enough DNA to perform testing or other reasons. In these cases, another sample may need to be sent to the laboratory to perform testing.

NGS PANEL REQUISITION

Patient Last Name Patient First Name MI / / _____
Date of Birth (MM / DD / YYYY) Genetic Sex

INFORMED CONSENT FOR GENETIC TESTING ON THE NGS PANEL REQUISITION

CONSIDERATIONS AND LIMITATIONS CONTINUED

- If several family members are tested, the correct interpretation of the results depends on the information provided about the relationships amongst family members. In rare cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. If a difference is identified, it may be necessary to share this information with the healthcare provider who ordered the testing.
- Genetic testing is highly accurate, however in rare cases, inaccurate results may occur. Reasons for this include, but are not limited to, mislabeled samples, inaccurate reporting of clinical/medical information, or rare technical errors.
- If you sign this consent form, but you no longer wish to have your sample(s) tested, you can contact the healthcare provider who ordered the test to cancel the test. If you wish to cancel testing, the laboratory must be notified of the cancellation request before 5 PM CST the business day after the sample has begun testing. If the laboratory is not notified of your cancellation request until after this time, you will be charged for the full cost of the test(s).
- Only Baylor Genetics and Baylor Genetics contracted partners will have access to the sample(s) provided to conduct the requested testing. Results will only be released to the following person(s): (i) a licensed healthcare provider, (ii) those authorized in writing, (iii) the patient or their personal representative, and (iv) those allowed access to test results by law. I understand that I have the right to access any test results directly from Baylor Genetics by providing a written request. I also understand that laboratory raw data, while not routinely released as part of the testing process, can be requested by providing a written request or HIPAA Authorization Form.
- In rare cases, persons with genetic diagnoses have experienced problems with insurance coverage and employment. The U.S. Federal Government has enacted several laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws prohibit unauthorized disclosure of this information. For more information, you can visit www.genome.gov/10002077.
- Samples will be retained in the laboratory in accordance with the laboratory retention policy.
- After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring health care providers unless specific prior arrangements have been made.
- Samples from residents of New York State will not be included in research studies without your written consent and will not be retained for more than 60 days after receipt of the sample. No tests other than those authorized shall be performed on the biological sample.
- By signing this consent form, I understand and agree that variants identified may also be submitted to public databases, such as ClinVar. Such submission serves to contribute knowledge to the medical community. I understand that limited clinical information is also required for the submission of information to ClinVar's database and further that the contents of this limited clinical information may, although unlikely, include information that may identify me personally.
- It is possible that even if the test identifies the underlying genetic cause for the disease in your family, this information may not help in predicting the progression of disease or change management or treatment of disease.

FOR WHOLE EXOME SEQUENCING (WES) REFLEX ORDERS ONLY

INCIDENTAL FINDINGS

This test may also find changes in genes that cause symptoms or diseases not related to the reason for having the test. These are called Secondary Findings and are associated with clear and immediate medical significance to your health or the health of your family members.

Category I: ACMG Secondary Findings

The American College of Medical Genetics (ACMG) has published guidelines for the reporting of these types of medically actionable or secondary findings (PMID: 34012068). These guidelines include a list of genes, which are updated occasionally, that are considered medically actionable and indicate laboratories should report pathogenic (disease-causing) findings in these genes. In accordance with an update to this policy statement (PMID: 25356965), you may choose to opt-in to receive this information.

Category II: Other Incidental Findings

Medically actionable variants are changes found in genes known to be associated with disease but not associated with your current symptoms or clinical presentation. These variants are reported as they may cause severe, early-onset disease or may have implications for treatment and prognosis. You may choose to opt-in to receive this information.

OTHER CONSIDERATIONS

The report will not include findings in genes causing adult-onset progressive neurological diseases for which there is presently no prevention or cure. If the reason for testing includes symptoms that clearly indicate such a disease, we recommend pursuing targeted testing based on specific symptoms and not WES testing. However, if the reason for testing includes a clinical presentation for such a disease, then genes relating to this presentation may be reported.

Samples from biological parents may help facilitate interpretation of WES results. After the proband report is issued, parental samples received can be tested for just the changes in genes that are highly likely to be causative of disease in the affected individual. This follow-up testing for family members is available at an additional charge. Free testing for variants of unknown significance in the immediate family members is available with prior approval.

NGS PANEL REQUISITION

Patient Last Name Patient First Name MI / / _____
Date of Birth (MM / DD / YYYY) Genetic Sex

FOR WHOLE EXOME SEQUENCING (WES) REFLEX ORDERS ONLY

REPORTING CHOICES

Please read the statements below carefully and check the appropriate box and initial. Due to the nature of the methodology of this testing we are unable to guarantee that all pathogenic (disease-causing) variants in each option will be detected by WES.

For all options below: If neither box is checked, or if the form is not signed, the consent for these options will be interpreted as "NO."

SECONDARY FINDINGS

Pathogenic or likely pathogenic variants in genes included in the ACMG policy statement regarding recommendations for reporting of secondary findings will be reported as medically actionable on the WES report.

- YES Please report pathogenic or likely pathogenic variants in genes determined to be secondary findings by the ACMG policy statement.
- NO Please do NOT report pathogenic or likely pathogenic variants in genes included in the ACMG policy statement

INCIDENTAL FINDINGS

Pathogenic or likely pathogenic variants in genes known to be associated with disease but not associated with your current symptoms or clinical presentation will be reported as medically actionable on the WES report.

- YES Please report pathogenic or likely pathogenic variants in genes known to be associated with disease but not associated with your current symptoms or clinical presentation
- NO Please do NOT report pathogenic or likely pathogenic variants in genes known to be associated with disease but not associated with your current symptoms or clinical presentation

OPTION TO ALLOW RELEASE OF UPDATED RESULTS

If a possible diagnosis can be made with new information, we would like to issue an updated report to the physician who ordered your WES. This review does NOT include a complete review of all of your data.

- YES If new information regarding the clinical significance of changes in my WES becomes known, I would like Baylor Genetics to issue an updated report which includes this information to my physician who ordered this WES testing.
- NO Please do NOT issue an updated report if there is new information regarding the clinical significance of my WES that becomes known.

FINANCIAL AGREEMENT AND GUARANTEE

By signing this consent form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider. For insurance billing, I hereby authorize Baylor Genetics to bill my health insurance plan on my behalf, and further authorize Baylor Genetics to release any information to my insurance carrier which is reasonably required for billing. I additionally designate Baylor Genetics as my designated representative for purposes of appealing any denial of benefits by my insurance carrier. I irrevocably assign associated payment to Baylor Genetics, and direct that payment be made directly to Baylor Genetics. I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by Baylor Genetics as part of a verification of benefits investigation. I agree to be financially responsible for all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for unpaid services performed by Baylor Genetics on my behalf, I agree to endorse the insurance check as appropriate and forward such check to Baylor Genetics within thirty (30) days of receipt thereof, as payment towards Baylor Genetics' claim for services rendered. If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by Baylor Genetics.

I understand that a completed Advance Beneficiary Notice (ABN) is required for Medicare patients if the service is deemed not medically necessary.

Patient Name Patient Signature _____
Date Signed (MM / DD / YYYY)

NGS PANEL REQUISITION

Patient Last Name Patient First Name MI Date of Birth (MM / DD / YYYY) Genetic Sex

RESEARCH & RECONTACT CONSENT

Baylor Genetics participates in research relating to health, disease prevention, drug development, and other scientific purposes. Baylor Genetics may contact patients or their provider(s) directly as part of this research. I agree to allow Baylor Genetics to contact me or my provider(s) about possible research involving the sample(s) and/or information associated with this testing. I understand that patients generally receive no compensation for this participation in research. For more information on research at Baylor Genetics, please visit baylorgenetics.com.

If I wish to opt out of being recontacted for research purposes by Baylor Genetics, I understand that I may check the box below:

Please do not contact me regarding any research that uses information obtained from this testing.

For any research I may be contacted about, I prefer contact through the following methods (please check all that apply – if no choices are selected, contact will be made via secure email if possible):

Email Mail Phone

PATIENT AUTHORIZATION

By signing this statement of consent, I acknowledge that I have read, understand, and hereby grant my informed consent for genetic testing. I have received appropriate explanations from my healthcare provider about the planned genetic test(s) and possible results. I have been informed by my healthcare provider about the availability and importance of genetic counseling and have been provided with written information identifying a genetic counselor or medical geneticist who can provide such counseling services. All my questions have been answered and I have had the necessary time to make an informed decision about the genetic test(s).

I hereby give permission to Baylor Genetics to conduct genetic testing as recommended by my physician.

Patient Name Patient Signature Date Signed (MM / DD / YYYY)

Patient's Parent / Personal Representative* Name Patient's Parent / Personal Representative* Signature Date Signed (MM/DD/YY)

Relationship of Personal Representative* to the Patient Ordering Provider's Signature Date Signed (MM/DD/YY)

* If you are signing on behalf of the patient as the parent(s) and/or person with legal authority to act on behalf of the patient, you may be required to provide evidence of your authority.